UNIVERSITA DEGLI STUDI DELL'INSUBRIA

Their core work

The University of Insubria is an Italian public university based in Varese with a distinctive research profile spanning mathematical logic, targeted drug delivery, bioethics, and applied health technologies. Their chemistry and pharmaceutical teams develop peptide-drug and small-molecule conjugates for tumor therapy, while their mathematics department specializes in substructural and modal logics with applications in computational linguistics. They also contribute to ethics-of-science research (research integrity, organoid ethics) and applied health projects including assistive living platforms and radiotherapy dosimetry. This breadth makes them a versatile consortium partner who can cover both fundamental science and societal/ethical dimensions within a single project.

What they specialise in

How they've shifted over time

In 2015-2018, the university's H2020 work centered on foundational research: mathematical logic (SYSMICS), cancer biology (GLYCANC), and the first targeted drug delivery project (MAGICBULLET). From 2019 onward, their portfolio diversified sharply into applied domains — biocatalysis, IoT-enabled sports analytics, cybersecurity, medical imaging, assistive living, and neurotransmitter biology — while maintaining their drug conjugate thread through Magicbullet Reloaded. The ethics/responsible research line (VIRT2UE in 2018, HYBRIDA in 2021) also grew, suggesting the university is positioning itself as a partner that bridges technical research with societal and ethical oversight.

Moving from pure research in logic and chemistry toward applied biomedical technologies and responsible innovation, making them increasingly relevant for health-sector consortia that need both technical and ethical expertise.

How they like to work

Insubria operates exclusively as a consortium partner — they have coordinated zero H2020 projects, always joining as a participant or third party. With 236 unique partners across 36 countries, they are well-connected but do not concentrate on repeat partnerships, instead joining diverse consortia wherever their specific expertise is needed. This suggests they function as a reliable specialist contributor rather than a consortium organizer, which is useful for coordinators looking for a dependable partner to fill a defined role.

Across 16 projects they have worked with 236 unique partners in 36 countries, indicating a wide but non-concentrated European network. Their partnerships span Western, Northern, and Southern Europe without a strong geographic bias beyond Italy.

What sets them apart

What distinguishes Insubria is their unusual combination of deep mathematical logic expertise, medicinal chemistry for targeted therapies, and research ethics — three domains rarely found together. This makes them a strong fit for interdisciplinary projects that need formal methods, biomedical innovation, and ethical-societal reflection under one institutional roof. Their consistent track record as a participant (never coordinator) also means they bring low administrative overhead — they integrate into existing consortia without competing for leadership.

Highlights from their portfolio

• RAIS
  Their largest single grant (EUR 522,999) and a shift into IoT and data science for sports analytics, far from their traditional strengths.
• Magicbullet Reloaded
  Direct sequel to their 2015 MAGICBULLET project, demonstrating sustained commitment to peptide-drug conjugate research over nearly a decade.
• CONCORDIA
  Second-largest grant (EUR 480,000) in a major EU cybersecurity competence network, showing their capacity to contribute to large-scale digital security initiatives.